Why the study?
Does acenocoumarol improve clinical outcomes compared to phenprocoumon in patients with myocardial infarction or angina pectoris?
Population
More than 250 patients with myocardial infarction or angina pectoris
Comparison
Acenocoumarol vs Phenprocoumon
Design
Other
Follow-up
average almost three years
Authors
Loading...
Similar outcomes support either agent in ischemic heart disease; leaves open whether stability differences affect rare events.
Does acenocoumarol improve clinical outcomes compared to phenprocoumon in patients with myocardial infarction or angina pectoris?
Acenocoumarol and phenprocoumon demonstrate similar clinical efficacy and safety in patients with ischemic heart disease, despite phenprocoumon offering slightly more stable anticoagulation.
Fekkes et al. (1971) studied this question.